ASLAN Pharmaceuticals’ $42.2 Million Initial Public Offering

Davis Polk advised the joint book-running managers and representatives of the underwriters in the approximately $42.2 million initial public offering by ASLAN Pharmaceuticals Limited of 6,000,000 American Depositary Shares.

The ADSs are listed on the NASDAQ Global Select Market under the symbol “ASLN.”

BTIG, H.C. Wainwright & Co., CLSA, Leerink Partners and Piper Jaffray acted as joint book-running managers on the offering.

ASLAN Pharmaceuticals is a clinical-stage, oncology-focused biopharmaceutical company developing novel therapeutics for global markets. ASLAN targets diseases that are both highly prevalent in Asia and orphan indications in the United States and Europe.

The Davis Polk corporate team included partner Alan F. Denenberg (Picture) and associates Donald K. Lang, Randy Li and Katherine Schloss Ackerman. Counsel Michelle Ontiveros Gross and associate Jason J. Bang provided intellectual property and technology advice. Counsel Marcie A. Goldstein provided FINRA advice.


Involved fees earner: Alan Denenberg – Davis Polk & Wardwell; Donald Lang – Davis Polk & Wardwell; Randy Li – Davis Polk & Wardwell; Katherine Schloss Ackerman – Davis Polk & Wardwell; Michelle Ontiveros Gross – Davis Polk & Wardwell; Jason Bang – Davis Polk & Wardwell; Marcie Goldstein – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: CLSA; Piper Jaffray & Co; Leerink Partners; BTIG, LLC; H.C. Wainwright & Co.;


Author: Ambrogio Visconti